Fact sheet: Prevalence of diabetes among Hispanics in six U.
Point: postprandial glucose levels are a clinically important treatment target.
Monnier L, Benichou M, Charra-Ebrard S, Boegner C, Colette C.
Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of Hb A(1c).
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? Bergenstal R, Pearson J, Cembrowski GS, Bina D, Davidson J, List S. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. Initiating insulin glargine (GLAR) with a pen (Solostar™) vs a vial: Impact on utilization and outcomes in a national managed care database [abstract] 541-P. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. Injection-meal interval: recommendations of diabetologists and how patients handle it. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Relationship of fasting and hourly blood glucose levels to Hb A1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Sustained benefit of continuous glucose monitoring on A1C, glucose profiles, and hypoglycemia in adults with type 1 diabetes.